Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Buy
77
IVBXF Quote, Financials, Valuation and Earnings
Last price:
$5.98
Seasonality move
:
13.07%
Day range:
$5.98 - $5.98
52-week range:
$3.91 - $6.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.42x
P/B ratio:
5.41x
Volume:
--
Avg. volume:
510
1-year change:
19.5%
Market cap:
$9.7B
Revenue:
$1.3B
EPS (TTM):
-$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Innovent Biologics has -- downside to fair value with a price target of -- per share.
IVBXF vs. S&P 500
-
Over the past 5 trading days, Innovent Biologics has underperformed the S&P 500 by -2.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Innovent Biologics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innovent Biologics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Innovent Biologics reported revenues of --.
Earnings Growth
-
Innovent Biologics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Innovent Biologics reported earnings per share of --.
Enterprise value:
9B
EV / Invested capital:
--
Price / LTM sales:
7.42x
EV / EBIT:
--
EV / Revenue:
6.90x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-66.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
346.47x
Gross Profit (TTM):
$1.1B
Return On Assets:
-0.46%
Net Income Margin (TTM):
-1.01%
Return On Equity:
-0.75%
Return On Invested Capital:
-0.6%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-30 | 2024-04-30 | 2024-04-30 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.8B | $1.7B | $1.9B | $1.4B | |
| Total Assets | $1.8B | $2.5B | $2.5B | $2.9B | $3B | |
| Current Liabilities | $227.4M | $478.5M | $507.2M | $631.6M | $598.5M | |
| Total Liabilities | $467.6M | $927.7M | $994.1M | $1.1B | $1.2B | |
| Total Equity | $1.3B | $1.6B | $1.6B | $1.8B | $1.8B | |
| Total Debt | $180.6M | $374.7M | $449.8M | $496.8M | $385.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-30 | 2024-04-30 | 2024-04-30 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
IVBXF
Sector
Market Cap
$9.7B
$34.4M
Price % of 52-Week High
93.36%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
-4.05%
-0.82%
1-Year Price Total Return
19.5%
-39.44%
Beta (5-Year)
-0.125
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$6.00
200-day SMA
Buy
Level
$5.15
Bollinger Bands (100)
Buy
Level
4.38 - 5.58
Chaikin Money Flow
Buy
Level
2.3M
20-day SMA
Buy
Level
$5.80
Relative Strength Index (RSI14)
Buy
Level
59.78
ADX Line
Buy
Level
19.1
Williams %R
Neutral
Level
-20.8333
50-day SMA
Buy
Level
$5.43
MACD (12, 26)
Buy
Level
0.17
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Sell
Level
-1.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.7744)
Buy
CA Score
(Annual)
Level (0.2004)
Sell
Beneish M-Score
(Annual)
Level (-2.1859)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.4641)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Stock Forecast FAQ
In the current month, IVBXF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IVBXF average analyst price target in the past 3 months is --.
-
Where Will Innovent Biologics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innovent Biologics share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Innovent Biologics?
Analysts are divided on their view about Innovent Biologics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innovent Biologics is a Sell and believe this share price will rise from its current level to --.
-
What Is Innovent Biologics's Price Target?
The price target for Innovent Biologics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IVBXF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innovent Biologics is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of IVBXF?
You can purchase shares of Innovent Biologics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innovent Biologics shares.
-
What Is The Innovent Biologics Share Price Today?
Innovent Biologics was last trading at $5.98 per share. This represents the most recent stock quote for Innovent Biologics. Yesterday, Innovent Biologics closed at $5.98 per share.
-
How To Buy Innovent Biologics Stock Online?
In order to purchase Innovent Biologics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
73
EXOD alert for Apr 30
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
